Pfizer announces corporate restructuring, workforce reduction and trial adjustments

Pfizer confirmed a corporate restructuring and workforce reduction initiative, cancelled its Phase II renal basket trial (NCT06419205), and plans to launch an open-label extension of its Phase II SIGNAL-AA trial (NCT06018428), reflecting a shift in development priorities.

Detected & updated continuously · Source: Nebula